Correspondence 0001193125-24-026684 from Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc.
Date: Feb. 7, 2024 · CIK: 0001785279 · Accession: 0001193125-24-026684
AI Filing Summary & Sentiment
File numbers found in text: 333-276413
Referenced dates: February 6, 2024
Letter
VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Jenn Do, Angela Connell, Tyler Howes and Suzanne Hayes Metagenomi, Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed February 5, 2024 File No. 333-276413
Dear Ladies and Gentlemen:
This letter is submitted on behalf of Metagenomi, Inc. (the “Company”), in response to the comments of the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) with respect to the Company’s Registration Statement on Form S-1 filed on January 5, 2024, as amended by Amendment No. 1 to Registration Statement on Form S-1, filed on January 8, 2024, and Amendment No. 2 to Registration Statement on Form S-1, filed on February 5, 2024 (the “Registration Statement”), as set forth in the Staff’s letter, dated February 6, 2024, addressed to Brian Thomas, Ph.D. (the “Comment Letter”). The Company is concurrently publicly filing the Amendment No. 3 to the Registration Statement on Form S-1 (the “Amendment No. 3”).
For reference purposes, the text of the Comment Letter has been reproduced herein with responses below each numbered comment. For your convenience, we have italicized the reproduced Staff comments from the Comment Letter. Unless otherwise indicated, page references in the descriptions of the Staff’s comments refer to the Registration Statement, and page references in the responses refer to the Amendment No. 3. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Amendment No. 3.
Amendment No. 2 to Registration Statement on Form S-1
Use of Proceeds, page 94
1. We note that you intend to fund continued research and development of your therapeutic portfolio including preclincial studies and advancement through preclinical proof-of-concept, and at least two IND filings for “certain” of your preclinical programs with the
proceeds from this offering. Please clarify if the continued research and development will be allocated evenly across all of your programs and if you have determined which of your preclinical programs you will fund with the proceeds from this offering. To the extent these programs are known, please also revise to disclose them in your Use of Proceeds section. If you have not determined which preclinical programs you will fund with proceeds from the offering, please explain how you will determine which programs to fund.
RESPONSE: The Company acknowledges the Staff’s comment and has revised its disclosure on pages 12 and 94 of Amendment No. 3 in response to the Staff’s comment.
If you should have any questions concerning the enclosed matters, please contact the undersigned at (212) 813-8800.
Sincerely,
Enclosures
Show Raw Text
CORRESP 1 filename1.htm CORRESP Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 February 7, 2024 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Jenn Do, Angela Connell, Tyler Howes and Suzanne Hayes Re: Metagenomi, Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed February 5, 2024 File No. 333-276413 Dear Ladies and Gentlemen: This letter is submitted on behalf of Metagenomi, Inc. (the “Company”), in response to the comments of the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) with respect to the Company’s Registration Statement on Form S-1 filed on January 5, 2024, as amended by Amendment No. 1 to Registration Statement on Form S-1, filed on January 8, 2024, and Amendment No. 2 to Registration Statement on Form S-1, filed on February 5, 2024 (the “Registration Statement”), as set forth in the Staff’s letter, dated February 6, 2024, addressed to Brian Thomas, Ph.D. (the “Comment Letter”). The Company is concurrently publicly filing the Amendment No. 3 to the Registration Statement on Form S-1 (the “Amendment No. 3”). For reference purposes, the text of the Comment Letter has been reproduced herein with responses below each numbered comment. For your convenience, we have italicized the reproduced Staff comments from the Comment Letter. Unless otherwise indicated, page references in the descriptions of the Staff’s comments refer to the Registration Statement, and page references in the responses refer to the Amendment No. 3. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Amendment No. 3. Amendment No. 2 to Registration Statement on Form S-1 Use of Proceeds, page 94 1. We note that you intend to fund continued research and development of your therapeutic portfolio including preclincial studies and advancement through preclinical proof-of-concept, and at least two IND filings for “certain” of your preclinical programs with the 1 proceeds from this offering. Please clarify if the continued research and development will be allocated evenly across all of your programs and if you have determined which of your preclinical programs you will fund with the proceeds from this offering. To the extent these programs are known, please also revise to disclose them in your Use of Proceeds section. If you have not determined which preclinical programs you will fund with proceeds from the offering, please explain how you will determine which programs to fund. RESPONSE: The Company acknowledges the Staff’s comment and has revised its disclosure on pages 12 and 94 of Amendment No. 3 in response to the Staff’s comment. If you should have any questions concerning the enclosed matters, please contact the undersigned at (212) 813-8800. Sincerely, Enclosures /s/ Edwin M. O’Connor Edwin M. O’Connor, Esq. cc: Brian C. Thomas, Ph.D., Metagenomi, Inc. Mitchell S. Bloom, Esq., Goodwin Procter LLP Justin S. Platt, Esq., Goodwin Procter LLP 2